(NASDAQ: EVAX) Evaxion A's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.6%.
Evaxion A's earnings in 2026 is -$11,974,000.On average, 5 Wall Street analysts forecast EVAX's earnings for 2026 to be -$223,890,900, with the lowest EVAX earnings forecast at -$424,031,489, and the highest EVAX earnings forecast at -$6,632,401. On average, 4 Wall Street analysts forecast EVAX's earnings for 2027 to be -$6,442,904, with the lowest EVAX earnings forecast at -$6,190,241, and the highest EVAX earnings forecast at -$6,632,401.
In 2028, EVAX is forecast to generate $4,832,178 in earnings, with the lowest earnings forecast at -$6,190,241 and the highest earnings forecast at $16,581,002.